METHODS: PubMed, Embase, Web of Science, and CNKI were searched systematically from inception until December 20, 2023. Studies involving TAMs and prognosis, clinical, or pathological features were included. Quality assessments of the selected studies were assessed. The fixed-effect or random-effects model, standard mean difference (SMD), odds ratios (OR), or hazard ratios (HR) with 95% confidence intervals (CIs) were used as the effect size estimate.
RESULTS: 26 eligible studies with 2,295 patients were identified. Our meta-analysis revealed that TAMs were overexpressed in CC (OR = 12.93, 95% CI = 7.73-21.61 and SMD = 1.58, 95% CI = 0.95-2.21) and that elevated TAM levels were strongly associated with lymph node metastasis (LNM) (SMD = 0.51, 95% CI = 0.90-2.01) and FIGO stages (SMD = 0.46, 95% CI = 0.08-0.85). Subgroup analysis indicated a significant positive correlation between LNM and TAMs density in tumor stroma, but not in cancer nests (SMD = 0.58, 95% CI = 0.31-0.58). Furthermore, in early stage, a stronger correlation exists between LNM and TAM density (SMD = 1.21, 95% CI = 0.75-1.66). In addition, it revealed that patients with high TAMs expression had poorer overall survival (OS) (HR = 2.55 95% CI = 1.59-4.07) and recurrence-free survival (RFS) (HR = 2.17, 95% CI = 1.40-3.35).
CONCLUSIONS: Our analyses suggest that a high density of TAMs predicts adverse outcomes in CC.
方法:PubMed,Embase,WebofScience,从成立之初到2023年12月20日,对CNKI进行了系统搜索。涉及TAM和预后的研究,临床,或包括病理特征。对所选研究的质量评估进行评估。固定效应或随机效应模型,标准平均差(SMD),赔率比(OR),或具有95%置信区间(CIs)的风险比(HR)被用作效应大小估计.
结果:确定了26项符合条件的研究,共2,295例患者。我们的荟萃分析显示,TAM在CC中过表达(OR=12.93,95%CI=7.73-21.61和SMD=1.58,95%CI=0.95-2.21),并且TAM水平升高与淋巴结转移(LNM)(SMD=0.51,95%CI=0.90-2.01)和FIGO分期(SMD=0.46,95%CI=-0.08)密切相关。亚组分析显示肿瘤间质中LNM与TAMs密度呈显著正相关,但不在癌巢中(SMD=0.58,95%CI=0.31-0.58)。此外,在早期阶段,LNM和TAM密度之间存在较强的相关性(SMD=1.21,95%CI=0.75-1.66)。此外,结果显示,TAMs高表达患者的总生存期(OS)(HR=2.5595%CI=1.59~4.07)和无复发生存期(RFS)(HR=2.17,95%CI=1.40~3.35)较差.
结论:我们的分析表明,高密度的TAM可预测CC的不良结局。